ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1884

Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska

Vivek Mehta and Elizabeth Ferucci, Alaska Native Tribal Health Consortium, Anchorage, AK

Meeting: ACR Convergence 2022

Keywords: Minority Health, Myopathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Racial disparities have been in noted in various autoimmune disorders. Indigenous North American populations have higher prevalence and severity of a number of autoimmune disorders, but few studies have examined the clinical characteristics of Idiopathic Inflammatory Myopathies (IIM) in Indigenous North American populations. We sought to describe the clinical characteristics of IIM patients in the Alaska Native/American Indian (AN/AI) population in Alaska.

Methods: This study was approved by the Alaska Area IRB as expedited research with a waiver of consent. Tribal approval was obtained from participating regional tribal health organizations. Potential cases were identified by a query of administrative data from the electronic health records for International Classification of Diseases (ICD)-9 and ICD-10 codes possibly identifying IIM during the period from 2012-2019. A detailed medical record abstraction was performed for each potential case. Cases were required to be confirmed by a medical provider. Clinical characteristics are reported based on medical record abstraction, including demographics, IIM subtype, organ involvement, serologies, and medications prescribed.

Results: A total of 42 people with IIM were identified. Of these, 12 had polymyositis (PM), 10 had dermatomyositis (DM), 6 had inclusion body myositis (IBM), and 7 had immune-mediated necrotizing myositis (IMNM). The mean age at IIM diagnosis was 54.1 years (standard deviation 16.8). IIM was more common in women (n=27, 64.3%) than men (n=15, 35.7%). Cutaneous manifestations (n=12, 28.6%), dysphagia (n=11, 26.2%), arthritis (n=11, 26.2%), and Raynaud’s (n=7, 16.7%) were some of the common clinical features. Interstitial lung disease (ILD) was noted in 6 patients (14.3%). Myositis specific antibodies were noted in 13 patients (30.1%). The most common disease-modifying anti-rheumatic drugs (DMARDs) ever prescribed included methotrexate (n=23), azathioprine (n=18), intravenous immunoglobulin (IVIG) (n=16), hydroxychloroquine (n=15), mycophenolate mofetil (n=11), and rituximab (n=8).

Conclusion: This is first study to describe clinical characteristics of IIM in AN/AI people in Alaska. Consistent with other data, PM and DM were the main IIM subtypes observed. However, IMNM was noted be more frequent compared to other populations. Cutaneous manifestations, dysphagia, arthritis, Raynaud’s, and ILD were commonly observed clinical manifestations.


Disclosures: V. Mehta, None; E. Ferucci, None.

To cite this abstract in AMA style:

Mehta V, Ferucci E. Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/idiopathic-inflammatory-myopathies-in-alaska-native-american-indian-people-in-alaska/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/idiopathic-inflammatory-myopathies-in-alaska-native-american-indian-people-in-alaska/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology